The diagnosis, treatment, and long-term monitoring of patients with autoinflammatory type 1 interferonopathies require a multidisciplinary approach, according to joint guidelines released by EULAR and the American College of Rheumatology.
The new points to consider, published in the Annals of the Rheumatic Diseases, cover the diagnosis and management of patients with chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS), stimulator of interferon genes-associated vasculopathy with onset in infancy